• Save
Erectile Dysfunction And Tadalafil
Upcoming SlideShare
Loading in...5
×
 

Erectile Dysfunction And Tadalafil

on

  • 2,483 views

 

Statistics

Views

Total Views
2,483
Views on SlideShare
2,477
Embed Views
6

Actions

Likes
0
Downloads
0
Comments
1

1 Embed 6

http://www.slideshare.net 6

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • highly informative Apreciable.presentation Will u pl add something to help the patients taking nitrates for more than 5 Years and also for those who have stopped taking nitrates for more than month Is there any relationship between ejection fraction and tadalafil action
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Erectile Dysfunction And Tadalafil Erectile Dysfunction And Tadalafil Presentation Transcript

  • DR B. K. IYER MEDICAL ADVISOR SHELYS PHARMACEUTICALS, TANZANIA Erectile dysfunction! A growing problem
  • Definition & Classification of ED
    • The consistent inability to obtain and maintain penile erection sufficient to complete satisfactory sexual performance.
      • Most men have difficulty having an erection from time to time due to stress, tiredness, alcohol, ‘not in the mood’.
      • If persistent and prevents normal sex life, disrupting relationship.
      • Severity grading done by IIEF-5 scoring.
  • IIEF5 parameters
  • Is ED common?
    • ED is a growing problem. Age variable most strongly associated with ED. Ageing population increasing problem
      • 1/3 ♂ over 50 yrs old,
      • 52% mild difficulty,
      • 10% with complete ED
    • Increase prevalence due to: DM, HTN, CVD, Anxiety + Depression
    • Risk factors: age, smoking and obesity
    • Non-diabetic men 0.1-18.4% prevalence but in a study of 541 diabetic males = 35% incidence
  • Causes of ED
    • Multifactorial with 80% cause being organic
    • Vascular:
      • uncontrolled DM, cardiac, vascular disease
      • new or complicated anti-HTN Rx
    • Neurogenic:
      • Spinal cord injury
      • Neurological disease (e.g. MS)
    • Hormonal:
      • ↓ testosterone, ↑ prolactin
      • TSH (rare cause hypothyroid)
    • Organic (focal):
      • BPH
      • liver/kidney disease
    • Medication: antidepressants, antihypertensives (ACE inhib + b-blocker)
  • History, examination and investigations
    • Patient’s description of the problem
    • Patient’s and partners expectations
    • Duration
    • Speed of onset
    • Intermittent/progressive?
    • History of sexual partners
    • Nocturnal erections?
    • Libido
    • Review medication
    • Basic explanation of physiology of erection
    • BP
    • Reflexes / Basic Neurological exam
    • Scrotum / penis
    • Urine sample (protein, glucose)
    • Blood:
      • testosterone,prolactin, glucose, cholesterol, TSH
      • PSA
  • Distinguishing psychogenic and organic ED Droupy S et al. (2006) How, why and when should urologists evaluate male sexual function? Nat Clin Pract Urol 3: 84 – 94 doi:10.1038/ ncpuro406
  • Treatment or referral
    • Self help: ↓ alcohol, ↓ smoking, ↓stress, ↓weight.
    • Discussion therapies
    • Medication: Phosphodiesterase-5 (PDE-5) inhibitors.
      • Only if specific medical condition or severe distress
    • Physical: vacuum device, rods and tubes
    • Topical medicines: alprostadil, papaverine
    • Referral: urology, neurology, endocrinology, counselling.
      • Urology, if PDE-5 failure or History / exam suggests primary ED
  • WITH FOCUS ON TADALAFIL PDE5 inhibitors
  • PDE-5 inhibitors
    • Sildenafil
    • Tadalafil
    • Vardenafil
      • Used in ED due to the following conditions
        • DM
        • PD, MS, poliomyelitis
        • Spinal cord injuries, spina bifida
        • Radical prostatectomy
    • Trial of 8 doses with dose titration before classifying as failure of treatment
    • Once correct dose achieved then can prescribe one tablet per week
  • PDE-5 Inhibitors
    • Contraindications:
      • Low BP, Nitrates, multidrug anti-HTN medication, allergies
    • Side effects:
      • headache, flushing, rhinitis, dyspepsia
  • MOA of PDE5 5 inhibitors
    • Induces smooth-muscle relaxation in cavernosal arteries & in peripheral circulation
  • MOA of PDE5 5 inhibitors
  • Comparison of sildenafil, vardenafil, tadalafil
    • They all are all PDE5 inhibitors with the same mechanism of action and similar adverse effects.
    • They all require sexual stimulation as a prerequisite and are effective regardless of the cause of erectile dysfunction.
    • Sidenafil has been around the longest and thus has the benefit of having long-term safety data.
      • However, it is also administered in higher doses than the others.
  • Comparison of sildenafil, vardenafil, tadalafil PDE5 inhibitor Duration Sildenafil 12 hours Vardenafil 4-5 hours Tadalafil 36 hours Vardenafil, however, is the most potent (lowest maximal concentration) and binds to PDE5 more rapidly than the others, thus it has a potential time of onset of 10 minutes.
  • Tadalafil
    • Administered orally
      • 10mg and 20mg doses
    • Instructions:
      • To take tadalafil 2 hours before sexual intercourse
    • Neither the consumption of a high-fat meal nor the timing of the dosing (morning or evening) had an effect on changes in plasma concentration or time to maximal response.
  • Tadalafil
    • Maximum dosing frequency is once every other day
      • Efficacy is maintained for at least 36 hours
        • Improved erections have been reported by 82.8% of treated men.
        • 36 hours after administration of Tadalafil, 59.2% of intercourse attempts were successful.
    • Side effects:
      • Headache, flushing, rhinitis and back pain/myalagia.
    • Precautions - Use with alpha-blockers: contraindicated except with tamsulosin 0.4 mg once daily
  • Tadalafil
    • Use in renal insufficiency: dose decreased to 5 mg once daily in moderate or severe renal insufficiency (creatinine clearance < 30 mL/minute); no data available in patients on dialysis
    • Safety concern:
      • It also serves as an inhibitor of PDE11, an enzyme in the testes, so there is concern on the effect that it has on sperm and spermatogenesis
      • High incidence of myopathy could be there if simvastatin is used concomitantly with CYP3A4 inhibitors such as PDE5 inhibitors as muscle toxicity is a potential adverse effect not only for statins, but also with PDE5 inhibitors .
  • Studies on Tadalafil on ED in Diabetic men
    • 191 (88%) of 216 patients completed the study.
    • Treatment with tadalafil significantly improved all primary efficacy variables, regardless of baseline HbA1c level but tadalafil did not alter mean HbA1c levels.
    • Tadalafil was well tolerated,
      • Headache and dyspepsia were the most frequent adverse events.
  • Tadalafil – performance on IIEF5 parameters Overall baseline Placebo, n-122 Tadalafil, n-126
  • Tadalafil - performance on dosage increase
  • Tadalafil - performance on dosage increase
  • Daily Tadalafil prevents ED in Diabetic men
    • A randomized, double-blind, placebo-controlled, multicenter, 12-week study of 298 diabetic men with erectile dysfunction was done by 9 investigators in Greece to study whether once-daily use of smaller doses, 2.5 or 5 mg, would also work.
    • Parameters measured included:
      • patient satisfaction,
      • vaginal penetration,
      • completion of intercourse, and
      • the International Index of Erectile Function Domain scores to assess success.
    • Adverse effects included back pain, headache, and dyspepsia.
    • Low dose taken daily produced statistically significant improvement.
    Medscape J Med. 2008; 10(5): 127 by George D. Lundberg.
  • CLASS EFFECT OR MOLECULE EFFECT? Bonus effects of Tadalafil
  • Tadalafil and metabolic syndrome
    • PDE5 inhibition may not only help in improving ED in diabetic male patients but also in improving β-cell function in metabolic syndrome.
    Diabetes Care May 2009 vol. 32 no. 5 857-859 by Kevin D. Hill et al.
    • Tadalafil, alone or in combination with ramipril, improved basal and glucose-stimulated β-cell function.
    • The metabolic improvement effect was independent of insulin sensitivity, as indicated by improvement in the disposition index
  • Tadalafil and cardiovascular medicine
    • Pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD) is incurable and it has an unpredictable survival rate .
    The Korean Journal of Internal Medicine : 22:37-39, 2007, Use of Tadalafil for treating PAH Secondary to COPD by Hyun-Sook Kim et al .
    • Patients suffering from COPD with progressive dyspnea and edema, viz. PAH, were prescribed tadalafil 10 mg orally every other day in addition to the baseline therapy for their depressed ventilatory function for 2 weeks
    • Then the dosage was doubled. The medication was well tolerated without any notable side effects.
    • After 4 weeks of tadalafil treatment, the patients' pulmonary arterial pressure was decreased and the MPI of the RV [myocardial performance index] improved.
    • The exercise capacity, as measured by the respiratory oxygen uptake, also improved.
  • Tadalafil and PAH and beyond
    • Thus, PDE5 inhibition by Tadalfil has been shown to be effective for the treatment of idiopathic PAH.
    • This therapeutic potential also extends to
      • Raynaud's phenomenon,
      • heart failure,
      • essential hypertension and
      • stroke.
    • Therapy of heart failure is the indication where PDE-5 inhibitors seem to find clinical application but preclinical data also support a role in cardiac preconditioning.
    Curr Pharm Des. 2009;15(30):3521-39. PDE5 inhibitors in non-urological conditions by Vlachopoulos C, et al. Curr Pharm Des. 2009;15(30):3540-51. Phosphodiesterase-5 inhibitors: future perspectives by Konstantinos G et al
  • Problems with PDE5 inhibitors
    • Despite the fact that more than 50 million ED patients have been treated successfully worldwide with PDE5 inhibitors, several issues remain to be addressed.
      • Patients with severe neurologic damage, diabetes mellitus, or severe vascular disease may be resistant to PDE5 inhibitors.
      • Inappropriate instructions, lack of follow-up and lack of patient-care models have been identified as main reasons for &quot;nonresponse&quot;, with drop-out rates of even > 50%.
    Curr Pharm Des. 2009;15(30):3476-85. Phosphodiesterase type 5 inhibitors: unmet needs by Hatzimouratidis K, Hatzichristou DG..
  • Problems of ED in patients with heart disease
    • The ACC/AHA consensus statement about the groups of patients at risk of potentially hazardous cardiovascular effects of PDE-5 inhibitors.
      • Patients with active coronary ischemia , even who are not taking nitrate ( positive ETT )
      • Patients with HF and borderline low BP and /or low volume status .
      • Patients on a complicated multidrug antihypertensive drugs regimen .
      • Patients taking drugs that prolong the half life of PDE5 inhibitors by blocking CYP 3A4
  • Thank you!